Methods for treating attention-deficit/hyperactivity disorder

Abstract

The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

1 . A method of treating ADHD, comprising the administration of a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment: 
       
         
           
           
               
               
           
         
         wherein 
         R is selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; 
         x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; 
         R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; 
         R 1  and R 2  can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom. 
       
     
     
         2 . The method of  claim 1 , wherein R is hydrogen and x=1. 
     
     
         3 . The method of  claim 1 , wherein R, R 1  and R 2  are hydrogen and x=1. 
     
     
         4 . The method of  claim 1 , wherein the compound having structural Formula (1) is an enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of the compound having structural Formula (1) predominates. 
     
     
         5 . The method of  claim 4 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         6 . The method of  claim 5 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         7 . The method of  claim 4 , wherein the enantiomer is (S) or (L) enantiomer as represented by Structural Formula (1a): 
       
         
           
           
               
               
           
         
         wherein R, x, R 1  and R 2  are as previously defined. 
       
     
     
         8 . The method of  claim 7 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         9 . The method of  claim 8 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         10 . The method of  claim 7 , wherein Rx, R 1  and R 2  are hydrogen and 
     
     
         11 . The method of  claim 4 , wherein the enantiomer is (R) or (D) enantiomer, as represented by Structural Formula (1b): 
       
         
           
           
               
               
           
         
         wherein R, x, R 1  and R 2  are as previously defined. 
       
     
     
         12 . The method of  claim 11 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         13 . The method of  claim 12 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         14 . The method of  claim 11 , wherein the enantiomer is (R)-(beta-amino-benzenepropyl) carbamate. 
     
     
         15 . The method of  claim 14 , wherein the enantiomer of (R)-(beta-amino-benzenepropyl) carbamate predominates to the extent of about 90% or greater. 
     
     
         16 . The method of  claim 15 , wherein the enantiomer of (R)-(beta-amino-benzenepropyl) carbamate predominates to the extent of about 98% or greater. 
     
     
         17 . A pharmaceutical composition for comprising a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof. 
       
         
           
           
               
               
           
         
         wherein 
         R is selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; 
         x is an integer of 1 to 3, with the proviso that R may be the same or different when x is ;2 or 3; 
         R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; 
         R 1  and R 2  can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.